Server cans autism hope bumetanide after phase 3 failsServier and Neurochlore have been forced to admit defeat in their bid to bring the first drug to Share XServer cans autism hope bumetanide after phase 3 failshttps://pharmaphorum.com/news/server-cans-autism-hope-bumetanide-after-phase-3-fails/
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios dealJust three months after completing its $1.8 billion takeover of Agios’ oncology pipeline, Servier has reported positive results Share XServier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios dealhttps://pharmaphorum.com/news/servier-gets-a-win-for-cancer-drug-tibsovo-bought-in-1-8bn-agios-deal/
Scotland backs rare blood cancer drug Poteligeo rejected by NICEA north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Share XScotland backs rare blood cancer drug Poteligeo rejected by NICEhttps://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/
Servier beefs up in cancer, buying Agios’ oncology business for $1.8bnFrench pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise Share XServier beefs up in cancer, buying Agios’ oncology business for $1.8bnhttps://pharmaphorum.com/news/servier-cancer-agios-oncology/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
Servier to acquire Danish cancer biotech SymphogenFrance’s Servier has signed a deal to buy the Danish biotech Symphogen, which specialises in antibody-based therapies for Share XServier to acquire Danish cancer biotech Symphogenhttps://pharmaphorum.com/news/servier-to-acquire-danish-biotech-symphogen/
Servier reveal how they are using data to empower their field forceThe French independent pharmaceutical Servier is putting data at the foundation of its customer relationship management strategy. Sebastien Share XServier reveal how they are using data to empower their field forcehttps://pharmaphorum.com/sales-marketing/servier-reveal-how-they-are-using-data-to-empower-their-field-force/
France’s Servier finally goes on trial over Mediator safety scandalMore than a decade after a scandal over drug safety in France first broke, the pharma company Servier Share XFrance’s Servier finally goes on trial over Mediator safety scandalhttps://pharmaphorum.com/news/frances-servier-finally-goes-on-trial-over-mediator-safety-scandal/
Servier and Oncodesign announce Parkinson’s R&D tie-upServier and Oncodesign have announced a strategic partnership for R&D into potential drug candidates for Parkinson’s disease. The Share XServier and Oncodesign announce Parkinson’s R&D tie-uphttps://pharmaphorum.com/news/servier-and-oncodesign-announce-parkinsons-rd-tie-up/
